Medilac-S作为常规肠易激综合征辅助治疗的有效性:一项系统综述和荟萃分析

IF 1.5 Q3 GASTROENTEROLOGY & HEPATOLOGY Gastroenterology Insights Pub Date : 2023-10-27 DOI:10.3390/gastroent14040036
Annie Tremblay, Xiaoyu Xu, James Colee, Thomas A. Tompkins, Sylvie Binda
{"title":"Medilac-S作为常规肠易激综合征辅助治疗的有效性:一项系统综述和荟萃分析","authors":"Annie Tremblay, Xiaoyu Xu, James Colee, Thomas A. Tompkins, Sylvie Binda","doi":"10.3390/gastroent14040036","DOIUrl":null,"url":null,"abstract":"Numerous clinical studies published in the Chinese language support the use of Medilac-S (Bacillus subtilis R0179 and Enterococcus faecium R0026; non-commercial name IBacilluS+) as an adjuvant in various indications, including ulcerative colitis, irritable bowel syndrome, acute gastritis, and Helicobacter pylori therapy. This systematic review with a meta-analysis was conducted to summarize clinical studies evaluating the efficacy of this probiotic formulation as an adjuvant to conventional IBS medications. The systematic literature searches in six international and Chinese databases identified 37 eligible studies, of which 33 reported the efficacy of Medilac-S adjunctive therapy using a standardized categorical scale. These 33 studies were included in the meta-analysis using a random-effect model with a stratification by IBS subtype. Overall, Medilac-S significantly improved the efficacy of conventional IBS treatment (RR = 1.21; 95% CI: 1.17–1.25; and p < 0.0001) with an average probability of treatment effectiveness being 21% higher with the probiotic adjuvant, regardless of the subtype. Adverse events, reported in 78% of the trials, were described as mild-to-moderate and self-resolving, with a similar incidence in the probiotic adjuvant (6.2%; n = 1347) and control (5.9%; n = 1331) groups. The results of this meta-analysis strengthen the conclusions that Medilac-S is a safe and effective adjuvant to a variety of conventional treatments in IBS patients.","PeriodicalId":43586,"journal":{"name":"Gastroenterology Insights","volume":"17 10","pages":"0"},"PeriodicalIF":1.5000,"publicationDate":"2023-10-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Effectiveness of Medilac-S as an Adjuvant to Conventional Irritable Bowel Syndrome Treatments: A Systematic Review with Meta-Analysis\",\"authors\":\"Annie Tremblay, Xiaoyu Xu, James Colee, Thomas A. Tompkins, Sylvie Binda\",\"doi\":\"10.3390/gastroent14040036\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"Numerous clinical studies published in the Chinese language support the use of Medilac-S (Bacillus subtilis R0179 and Enterococcus faecium R0026; non-commercial name IBacilluS+) as an adjuvant in various indications, including ulcerative colitis, irritable bowel syndrome, acute gastritis, and Helicobacter pylori therapy. This systematic review with a meta-analysis was conducted to summarize clinical studies evaluating the efficacy of this probiotic formulation as an adjuvant to conventional IBS medications. The systematic literature searches in six international and Chinese databases identified 37 eligible studies, of which 33 reported the efficacy of Medilac-S adjunctive therapy using a standardized categorical scale. These 33 studies were included in the meta-analysis using a random-effect model with a stratification by IBS subtype. Overall, Medilac-S significantly improved the efficacy of conventional IBS treatment (RR = 1.21; 95% CI: 1.17–1.25; and p < 0.0001) with an average probability of treatment effectiveness being 21% higher with the probiotic adjuvant, regardless of the subtype. Adverse events, reported in 78% of the trials, were described as mild-to-moderate and self-resolving, with a similar incidence in the probiotic adjuvant (6.2%; n = 1347) and control (5.9%; n = 1331) groups. The results of this meta-analysis strengthen the conclusions that Medilac-S is a safe and effective adjuvant to a variety of conventional treatments in IBS patients.\",\"PeriodicalId\":43586,\"journal\":{\"name\":\"Gastroenterology Insights\",\"volume\":\"17 10\",\"pages\":\"0\"},\"PeriodicalIF\":1.5000,\"publicationDate\":\"2023-10-27\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Gastroenterology Insights\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.3390/gastroent14040036\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q3\",\"JCRName\":\"GASTROENTEROLOGY & HEPATOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Gastroenterology Insights","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.3390/gastroent14040036","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"GASTROENTEROLOGY & HEPATOLOGY","Score":null,"Total":0}
引用次数: 0

摘要

中文发表的大量临床研究支持使用Medilac-S(枯草芽孢杆菌R0179和屎肠球菌R0026);非商业名称IBacilluS+)作为佐剂用于各种适应症,包括溃疡性结肠炎、肠易激综合征、急性胃炎和幽门螺杆菌治疗。本系统综述和荟萃分析总结了评估该益生菌制剂作为常规肠易激综合征药物辅助治疗效果的临床研究。系统检索了6个国际和中国数据库的文献,确定了37项符合条件的研究,其中33项采用标准化分类量表报告了Medilac-S辅助治疗的疗效。这33项研究采用随机效应模型按IBS亚型分层纳入meta分析。总体而言,Medilac-S显著提高了常规IBS治疗的疗效(RR = 1.21;95% ci: 1.17-1.25;p <0.0001),与亚型无关,使用益生菌佐剂治疗效果的平均概率高出21%。78%的试验报告的不良事件被描述为轻度至中度且可自行消退,益生菌佐剂的发生率相似(6.2%;N = 1347)和对照组(5.9%;N = 1331)组。本荟萃分析的结果加强了Medilac-S是IBS患者各种常规治疗的安全有效辅助的结论。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
Effectiveness of Medilac-S as an Adjuvant to Conventional Irritable Bowel Syndrome Treatments: A Systematic Review with Meta-Analysis
Numerous clinical studies published in the Chinese language support the use of Medilac-S (Bacillus subtilis R0179 and Enterococcus faecium R0026; non-commercial name IBacilluS+) as an adjuvant in various indications, including ulcerative colitis, irritable bowel syndrome, acute gastritis, and Helicobacter pylori therapy. This systematic review with a meta-analysis was conducted to summarize clinical studies evaluating the efficacy of this probiotic formulation as an adjuvant to conventional IBS medications. The systematic literature searches in six international and Chinese databases identified 37 eligible studies, of which 33 reported the efficacy of Medilac-S adjunctive therapy using a standardized categorical scale. These 33 studies were included in the meta-analysis using a random-effect model with a stratification by IBS subtype. Overall, Medilac-S significantly improved the efficacy of conventional IBS treatment (RR = 1.21; 95% CI: 1.17–1.25; and p < 0.0001) with an average probability of treatment effectiveness being 21% higher with the probiotic adjuvant, regardless of the subtype. Adverse events, reported in 78% of the trials, were described as mild-to-moderate and self-resolving, with a similar incidence in the probiotic adjuvant (6.2%; n = 1347) and control (5.9%; n = 1331) groups. The results of this meta-analysis strengthen the conclusions that Medilac-S is a safe and effective adjuvant to a variety of conventional treatments in IBS patients.
求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
Gastroenterology Insights
Gastroenterology Insights GASTROENTEROLOGY & HEPATOLOGY-
CiteScore
2.80
自引率
3.40%
发文量
35
审稿时长
10 weeks
期刊最新文献
Correlation between Interleukin-17, High Sensitivity C-Reactive Protein and Pepsinogen in Helicobacter pylori Infected Gastritis Elevated Incidence and Risk of Emergent Cirrhosis Complications in Alcoholic Cirrhosis Compared with Other Etiologies Insights into the Characteristics and Functions of Mast Cells in the Gut Terlipressin for the Prevention and Treatment of Renal Decline in Hepatorenal Syndrome: A Drug Profile. Microbiome and Genetic Factors in the Pathogenesis of Liver Diseases
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1